Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;134(4):582-588.
doi: 10.1111/bju.16332. Epub 2024 Mar 16.

Cost-effectiveness analysis of different treatment modalities in BCG-unresponsive NMIBC

Constantin Rieger  1 , Jörg Schlüchtermann  2 , Enno Storz  1 , Lucas Kastner  1 , David Pfister  1 , Axel Heidenreich  1   3
Affiliations

Cost-effectiveness analysis of different treatment modalities in BCG-unresponsive NMIBC

Constantin Rieger et al. BJU Int. 2024 Oct.

Abstract

Objective: Radical cystectomy (RC) is the standard of care (SOC) in BCG-unresponsive NMIBC and is associated with a significant health-related quality-of-life burden. Recently, promising results have been published on Gemcitabine/Docetaxel, Pembrolizumab, and Hyperthermic Intravesical Chemotherapy (HIVEC) as salvage therapy options trying to increase the rate of bladder preservation. Here, we performed a Cost-Effectiveness-Analysis of those treatment modalities.

Patients and methods: We developed a Markov model from a payer's perspective drawing on clinical data of single-arm trials testing intravesical gemcitabine/docetaxel and pembrolizumab in BCG-unresponsive NMIBC, as well as clinical data from patients receiving hyperthermic intravesical chemotherapy HIVEC (n = 29) as intravesical salvage chemotherapy at our uro-oncological centre in Cologne. Costs were simulated utilising a non-commercial diagnosis-related groups grouper, utilities were derived from comparable cost-effectiveness studies. We used a Monte Carlo simulation to identify the optimal treatment, comparing the incremental cost effectiveness ratios (ICERs) at a willingness-to-pay threshold of €50 000 (euro)/quality-adjusted life year (QALY).

Results: Over a horizon of 10 years, gemcitabine/docetaxel, HIVEC, and pembrolizumab were associated with costs of €48 353, €64 438, and €204 580, as well as a gain of QALYs of 6.16, 6.48, and 6.00, resulting in an ICER of €26 482, €42 567, and €184 533 respectively, in comparison to RC with total costs of €21 871 and a gain of QALYs of 5.01. Monte Carlo simulation identified HIVEC as the treatment of choice under assumption of a WTP of <€50 000.

Conclusion: Considering a WTP of <€50 000/QALY, gemcitabine/docetaxel and HIVEC are highly cost-effective therapeutic options in BCG-refractory NMIBC, while RC remains the cheapest option. At its current price, pembrolizumab would only be cost-effective assuming a price reduction of at least 70%.

Keywords: BCG unresponsive; HIVEC; bladder cancer; cost‐effectiveness; pembrolizumab.

PubMed Disclaimer

References

    1. Mossanen M, Gore JL. The burden of bladder cancer care: direct and indirect costs. Curr Opin Urol 2014; 24: 487–491
    1. Svatek RS, Hollenbeck BK, Holmäng S et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol 2014; 66: 253–262
    1. Michaeli JC, Boch T, Albers S, Michaeli T, Michaeli DT. Socio‐economic burden of disease: survivorship costs for bladder cancer. J Cancer Policy 2022; 32: 100326
    1. Cox E, Saramago P, Kelly J et al. Effects of bladder cancer on UK healthcare costs and patient health‐related quality of life: evidence from the BOXIT trial. Clin Genitourin Cancer 2020; 18: e418–e442
    1. Shirakawa H, Kikuchi E, Tanaka N et al. Prognostic significance of Bacillus Calmette‐Guérin failure classification in non‐muscle‐invasive bladder cancer. BJU Int 2012; 110(6 Pt B): E216–E221

MeSH terms

LinkOut - more resources